Acadia Healthcare cuts 2026 capex, expands beds

Acadia Healthcare Company, Inc. is providing preliminary 2026 guidance and an interim operating update alongside a conference appearance.

Rhea-AI Filing Summary

Acadia Healthcare Company, Inc. is providing preliminary 2026 guidance and an interim operating update alongside a conference appearance. For 2026, the company expects total capital expenditures to decline by at least $300 million compared with its 2025 capital expenditure guidance of $600 to $650 million, indicating a materially lower investment spend next year. Acadia also expects to add 500 to 700 beds in 2026, including beds already under construction in 2025, highlighting ongoing capacity expansion.

For the third quarter of 2025, Acadia is disclosing a select interim operating metric, reporting same facility patient days growth to date of approximately 1.3%. The company notes that forward-looking statements, including these expectations, are subject to risks such as integration of expansions and acquisitions, changes in government and commercial reimbursement, the impact of the One Big Beautiful Bill Act on Medicaid financing and eligibility, labor and cost pressures, cybersecurity risks, and broader economic conditions.

Insights

Healthcare services equity analyst

Acadia signals lower 2026 capex and modest volume growth.

Acadia Healthcare outlines a shift in its investment profile by guiding 2026 capital expenditures to be at least $300 million lower than its prior 2025 guidance of $600 to $650 million. This points to a slower spending pace on new projects or facility upgrades while still planning to add 500 to 700 beds in 2026, including beds now under construction. The combination suggests continued capacity growth with a more restrained capital outlay.

On current operations, Acadia reports same facility patient days growth to date in the third quarter of 2025 of about 1.3%, indicating modest volume improvement at existing facilities. The company pairs these disclosures with a detailed risk discussion, citing integration challenges from expansions and acquisitions, reimbursement pressure tied to the One Big Beautiful Bill Act, labor and cost inflation, potential patient incidents, and cybersecurity risks. Actual outcomes for 2026 capex, bed additions, and volume will depend on how these operational and policy factors evolve.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What preliminary 2026 capital expenditure guidance did Acadia Healthcare (ACHC) provide?

Acadia Healthcare expects its total capital expenditures in 2026 to decline by at least $300 million compared with its 2025 capital expenditure guidance of $600 to $650 million.

How many beds does Acadia Healthcare (ACHC) plan to add in 2026?

Acadia Healthcare expects to add 500 to 700 beds in 2026, and this figure includes beds that are already under construction in 2025.

What interim operating metric for Q3 2025 did Acadia Healthcare (ACHC) disclose?

For the third quarter of 2025, Acadia Healthcare reported same facility patient days growth to date of approximately 1.3%.

In what context did Acadia Healthcare (ACHC) share this guidance and update?

Members of Acadia Healthcare’s senior management are participating in a fireside chat at the Jefferies 2025 Healthcare Services Conference, and the company shared its preliminary 2026 guidance and interim Q3 2025 operating result in connection with that event.

Are Acadia Healthcares (ACHC) 2026 expectations and Q3 2025 update considered forward-looking statements?

Yes. The company states that this report contains forward-looking statements regarding strategy, growth, and anticipated operating results, including its 2026 capital expenditure and bed growth expectations, and these are subject to various risks and uncertainties.

What key risks could affect Acadia Healthcares (ACHC) future results?

Acadia highlights risks including integration of acquired or expanded facilities, its ability to add beds and expand services, reimbursement changes including those linked to the One Big Beautiful Bill Act, patient incidents and regulatory actions, debt service and capital needs, information technology and cybersecurity issues, and broader economic and industry conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/29/2025 - 07:05 AM Learn about SEC filing dates

false 0001520697 0001520697 2025-09-29 2025-09-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 29, 2025 (September 29, 2025)

Acadia Healthcare Company, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-35331		45-2492228
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

6100 Tower Circle, Suite 1000 Franklin, Tennessee		37067
(Address of Principal Executive Offices)		(Zip Code)

(615) 861-6000

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		ACHC		NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Members of the senior management team of Acadia Healthcare Company, Inc. (the “Company”) are scheduled to participate in a fireside chat at the Jefferies 2025 Healthcare Services Conference on September 29, 2025. In conjunction with this fireside chat, the Company today is announcing preliminary guidance for 2026 with respect to expected total capital expenditures and bed growth. Total capital expenditures are expected to decline at least $300 million relative to 2025 guidance of $600 to $650 million, as provided in its press release that was previously furnished as Exhibit 99 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2025. The Company also expects to add 500 to 700 beds in 2026, inclusive of beds currently under construction in 2025.

The Company is also providing a select interim operating result for the third quarter of 2025, announcing same facility patient days growth to date of approximately 1.3%. For an explanation of how same facility results are calculated and the Company’s rationale for presenting them to investors, please see Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the SEC on August 5, 2025.

The information furnished pursuant to Item 7.01 in this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Forward-Looking Information

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including statements related to the Company’s strategy, growth, and anticipated operating results for future periods. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this Current Report on Form 8-K. The Company does not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and the Company’s future results could differ significantly from those expressed or implied by the Company’s forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of the Company’s facility expansions, acquisitions, joint ventures and de novo transactions; (ii) the Company’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by the Company from government and commercial payors, including because of the significant changes to Medicaid financing mechanisms introduced by the One Big Beautiful Bill Act (“OBBBA”) enacted on July 4, 2025; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of the Company’s common stock and result in substantial payments and incremental regulatory burdens; (v) the risk that the Company may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vi) potential disruptions to the Company’s information technology systems or a cybersecurity incident; and (vii) potential operating difficulties, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes, including, without limitation, due to OBBBA’s introduction of work or community engagement requirements in the Medicaid expansion population; increased costs relating to labor, supply chain and other expenditures; changes in competition and client preferences; and general economic or industry conditions that may prevent the Company from realizing the expected benefits of its business strategies. These factors and others are more fully described in the Company’s periodic reports and other filings with the SEC.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 29, 2025				ACADIA HEALTHCARE COMPANY, INC.
				By:		/s/ Brian P. Farley
						Brian P. Farley
						Executive Vice President, Secretary and General Counsel